Recently, CHK1i has been shown to trigger cGAS-STING cytokine expression and an immune response that is enhanced with anti-PD-L1 in models of small cell lung cancer [64], demonstrating that CHK1i inhibitor based therapy is permissive for immune cell function and can trigger a tumour-directed immune response. The gene discussed is CGAS; the disease is neoplasm.